Clinical Trials
3 trialsNCT03797326 2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03609359 2025-04-16
Lenva+Pembro
National Cancer Center Hospital East
Phase 2 Completed
NCT03321630 2024-03-27
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
NYU Langone Health
Phase 2 Completed